Aster DM Healthcare launches myAster in Saudi Arabia, alongside AI and Generative AI-enabled Arabic voice response with Google Cloud
myAster app is a one-stop solution for all Aster services in the country - hospital, pharmacies and clinics (Aster Clinics will be launched in KSA soon). It will provide the user with easy access to doctor appointments, telehealth consultations, home delivery of pharmacy and wellness products and a wide range of wellbeing solutions. myAster also enables the user to track their health vitals, access lab reports, health records and manage chronic conditions, all from their fingertips, ensuring easy management of their health from anywhere, at any time.
Aster has committed to invest SAR 1 billion (USD 250 million) in Saudi Arabia over the next 2-3 years across hospitals, clinics, pharmacies and digital health to create an omnichannel health and wellness experience for the people in the Kingdom, in alignment with Vision 2030
Riyadh: Aster DM Healthcare, a leading integrated healthcare provider in the GCC, marks a significant milestone with the launch of its flagship digital health platform, myAster, in the Kingdom of Saudi Arabia. This launch aligns with Aster's ambitious plans to expand its footprint in the Kingdom and transform the healthcare experience for the people of the country.
With a proven track record as the UAE's No.1 wellbeing and healthcare app and over 2 million downloads, myAster is set to redefine digital healthcare in Saudi Arabia. The app offers an all-encompassing suite of services, including online pharmacy, prescription home delivery, appointment management, video consultation, and home care services.
As part of its launch at the prestigious LEAP 2025 event, myAster unveiled a groundbreaking feature: AI and gen AI voice integration in collaboration with Google Cloud. This advanced capability introduces Arabic voice response, allowing users to describe their symptoms in their native dialect for personalized and culturally relevant interactions. The AI-driven symptom analysis guides users to the most appropriate specialists or healthcare services within Aster's network. By bridging language barriers and enhancing accessibility, this innovation underscores Aster's dedication to delivering inclusive and patient-centric healthcare solutions in Saudi Arabia.
Designed to meet the diverse needs of users, myAster empowers individuals to track their health vitals, access lab reports and health records, and benefit from chronic disease management programs tailored to address lifestyle diseases such as diabetes and hypertension. With these features, myAster provides a comprehensive solution for users to proactively manage their wellness journey.
Commenting on the launch of myAster in Saudi Arabia, Alisha Moopen, Managing Director & Group CEO, Aster DM Healthcare said 'The launch of myAster in Saudi Arabia is a pivotal moment in our journey to bring integrated and accessible healthcare solutions to the Kingdom. With the introduction of myAster, we continue to lead the digital revolution in the GCC, reaffirming our commitment to building a future-ready healthcare ecosystem that prioritizes convenience, accessibility, and innovation.'
Nalla Karunanithy, CEO of Digital Health and E-Commerce, Aster DM Healthcare added ' myAster not only empowers individuals to take charge of their health but also bridges the gap between patients and specialists by guiding them to the right care based on real-time symptom analysis. By leveraging AI and collaborating with Google Cloud, we're setting a new standard for digital healthcare innovation. As we continue to innovate, our vision is to build a future where healthcare is not only smarter and more efficient but also deeply human-centered, meeting the unique needs of every individual we serve.'
"Unlocking solutions that empower customers remains the most critical component of every enterprise's digital transformation strategy,' said Bader Almadi, Google Cloud GM in Saudi Arabia at Google Cloud. 'Using Google Cloud's AI and generative AI technologies, Aster DM Healthcare aims to transform the patient experience with myAster. The introduction of Arabic voice response, powered by our advanced AI models, makes healthcare more accessible and personalized for the people of Saudi Arabia, demonstrating the potential of AI to revolutionize how healthcare is delivered.'
Aster DM Healthcare has pledged an investment of SAR 1 billion (USD 250 million) in Saudi Arabia over the next 2-3 years, demonstrating its unwavering commitment to enhancing healthcare in the region. This investment will support the expansion of Aster Pharmacy to 180 stores across the Kingdom, while also scaling bed capacity to 1,000 through the establishment of five new hospitals in major cities alongside the existing Aster Sanad Hospital.
Additionally, Aster plans to launch 30 medical centers to reinforce its integrated healthcare model and provide employment opportunities to approximately 4,900 people in the Kingdom over the next five years. The introduction of myAster is a pivotal component of this strategy, designed to deliver a seamless connected care experience for the residents of Saudi Arabia.
About Aster DM Healthcare FZC in GCC
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across all six countries: including 5 GCC countries and Jordan. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of 'We will treat you well'. The organisation's robust integrated healthcare model includes 16 hospitals, 120 clinics, and 307 pharmacies in GCC serving all segments of society through three differentiated brands: Aster, Medcare and Access. Aster consistently adapts to meet the evolving needs of patients, ensuring access to quality healthcare through both physical and digital channels which is exemplified with the launch of the region's first healthcare super app, myAster. With a steadfast focus on innovation and patient-centric approach, the organisation's dedicated team of 1806 doctors and 3826 nurses are committed to delivering world-class healthcare services across a diverse spectrum of medical and surgical specialties.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
2 hours ago
- Zawya
Hong Kong Hosts World's Largest ISSCR Stem Cell Gathering for the First Time
Some 2,400 stem cell and regenerative medicine pioneers convene to chart new frontiers, resulting from bidding efforts of Hong Kong Convention Ambassadors of the Hong Kong Tourism Board HONG KONG SAR - Media OutReach Newswire - 11 June 2025 - Reputed to be a leading research and development (R&D) hub for medical sciences, Hong Kong hosts the world's largest and most significant gathering of stem cell research and regenerative medicine, the International Society of Stem Cell Research (ISSCR) 2025 Annual Meeting. The event is brought to Hong Kong for the first time, thanks to the joint effort of three local universities – The University of Hong Kong, The Chinese University of Hong Kong and the Hong Kong University of Science and Technology, which are appointed organisations under the Hong Kong Convention Ambassador (HKCA) programme of the Hong Kong Tourism Board (HKTB). The four-day meeting held on June 11-14 gathers more than 2,400 local and international experts in stem cell research and regenerative medicine from 58 countries and regions, from Asia to North America, Europe, Australia, the Middle East, and Mainland China. Pioneers share the latest advances in the field, with topics spanning the field of regenerative medicine including topics such as advances in cell therapies, fundamental discoveries, understanding disease processes and more. Dr Peter Lam, HKTB Chairman, said, "The International Society for Stem Cell Research (ISSCR) is a globally leading organisation in medical sciences and research, and its annual meeting is one of the world's most significant international academic conventions in medical science. Hong Kong is the first city chosen to host this annual event in Asia after a 13-year hiatus, underscoring the city's status as the 'World's Meeting Place'. I am grateful for the active participation of the Hong Kong Convention Ambassadors from the three local universities, who leveraged their influence and network during the bidding for the host of the event to make the event come true. We are also delighted to see that more professionals from a wider range of expertise are joining HKTB's league of Convention Ambassadors, and we believe their participation can help identify and contribute to the staging of more significant international events in Hong Kong." Valentina Greco, ISSCR President, remarked, "Hosting ISSCR 2025 in Hong Kong marks a defining moment for global stem cell science. As a vibrant research hub at the crossroads of Asia and the world, Hong Kong offers an ideal setting to connect diverse scientific communities, spark new collaborations, and accelerate innovation. The ISSCR is deeply grateful to the city of Hong Kong and to our generous co-sponsors – the University of Hong Kong, The Chinese University of Hong Kong, and the Hong Kong University of Science and Technology – for their support and commitment to bringing The Global Stem Cell Event to this beautiful city. With the unwavering support of the Hong Kong Tourism Board, these three leading universities, and inspired leadership from our 2025 Annual Meeting Program Committee, this meeting exemplifies the power of partnership and shared vision. We are proud to return to Asia for the first time in more than a decade at a time when our collective progress in stem cell research and regenerative medicine and to advancing therapies that have life altering impact on patients depends on the exchange of bold ideas across borders." The extensive programme features plenary sessions, concurrent tracks, poster presentations, and networking opportunities. Contributing to the success of the event, the HKTB has provided comprehensive support, from arranging reconnaissance to venue sourcing, bid proposal, network support and more. Hong Kong Convention Ambassador Programme Aligns a Record Lineup of 180 Industry Leaders HKCAs have been instrumental in winning the ISSCR 2025 Annual Meeting for Hong Kong. Launched in 2020 by the HKTB as a strategic initiative, the HKCA programme recruits high-level representatives of Hong Kong's eight universities, chambers of commerce, professional organisations, public bodies, industrial entities and professional societies to act as ambassadors for Hong Kong's convention sector. With their professional influence and networks, HKCAs have led efforts to bring in events ranging from medical sciences to innovation and technology (I&T), financial services, aviation, transportation and more. The close collaboration between HKCAs and the HKTB has proven effective in promoting Hong Kong as a premier hub for world-class conventions. As an alliance of distinguished local and Mainland leaders in business, medicine, professional services, I&T and other fields, the HKCA programme has been growing from strength to strength, with 72 new members in the latest record-sized cohort for the 2025-2026 term, taking the total to about 180, some 30% more than the previous cohort. Among the 76 international events for 2025 to 2027 lined up by the HKTB, with an estimated attendance of over 180,000 MICE visitor arrivals and 27 resulted from HKCAs' efforts. The events cover diverse fields ranging from I&T to aviation and medical sciences. Some are held in Hong Kong for the first time, including IEEE Electron Devices Technology and Manufacturing Conference held in March 2025, Routes World in September 2025 and World Cancer Congress 2026. The HKTB is committed to working closely with HKCAs to welcome more world-class events to Hong Kong, attracting high-yield overnight business visitors to the city and reinforcing the city's status as the world's meeting place. Large-scale conventions facilitated by Hong Kong Convention Ambassadors: Date Events (*first-ever in Hong Kong) Theme/Sector March 2025 IEEE Electron Devices Technology and Manufacturing Conference * Innovation & Technology May 2025 IEEE International Conference on Data Engineering Innovation & Technology Jun 2025 International Society for Stem Cell Research (ISSCR) Annual Meeting* Medical sciences Sep 2025 Routes World* Aviation Dec 2025 The International Society of Sport Psychology 16 th World Congress Sports & Medical sciences 2026 Asia-Pacific Association for International Education 2026 Conference and Exhibition Education 2026 17 th Asian Congress of Oral and Maxillofacial Surgery Medical sciences 2026 Asian Venture Philanthropy Network Conference Philanthropy 2026 International Federation of Landscape Architects World Congress Architecture 2026 Lions International Convention Social Services 2026 The Association of National Olympic Committees General Assembly Sports 2026 The Council Meeting of the Asian Patent Attorneys Association Intellectual property 2026 World Cancer Congress* Medical sciences 2027 International Association for Energy Economics Annual International Conference Economics 2027 Lions Clubs International Orient and Southeast Asian Lions Forum Social Services 2027 World Organization of Family Doctors Asia Pacific Regional Conference Medical sciences Hashtag: #HKTB The issuer is solely responsible for the content of this announcement. Hong Kong Tourism Board
Arabian Post
3 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Khaleej Times
3 days ago
- Khaleej Times
'Legacy will live on': Hundreds gather in Dubai to mourn renowned Indian doctor
Hundreds of people gathered at Al Quoz cemetery late on Sunday to bid farewell to Dr Nazar Moopan, a well-loved member of the medical community and nephew of Dr Azad Moopen, Founder Chairman of Aster DM Healthcare. Well-wishers and friends flew in from India and other Gulf countries to pay their respects to the doctor who passed away peacefully in Dubai on Sunday, surrounded by his family. 'It is with deep sorrow and a profound sense of loss that we mourn the passing of Dr Nazar Moopan,' said Dr Azad Moopen. 'Dr Nazar was not only a pillar of our medical community but also a compassionate doctor, a committed leader, and a beloved colleague to many within the Aster family. For over two decades, Dr Nazar has worked at Aster DM Healthcare and at the time of his death, he was the Medical Director and ENT Consultant at the group's facility in Qatar. He is survived by his wife Wahida and his children Neda, Nimmi and Zain. According to Dr Azad, Dr Nazar 'dedicated his life to the service of others' for decades, exemplifying the values of integrity, excellence, and empathy. 'His contributions to healthcare in Qatar have left an indelible mark, and his legacy will live on through the countless lives he touched with his skill and kindness,' he said.
